Strategic Analysis Of Pfizer

1231 Words3 Pages
bulb-icon

Recommended: Company strategy formulation

1. INTRODUCTION
This is the second of three reports I will complete as part of the strategic analysis of Pfizer. This report focuses on strategy analysis and includes the following sections. First, the major concepts related to generic, corporate and international strategies analysis will be defined. Second, those concepts will be applied to the case of Pfizer in order to analyze its strategies. The analysis of Pfizer will be followed by its evaluation to identify the major problem the company is facing and propose a solution that Pfizer can adopt. A short conclusion will close the report.

2. CONCEPTS This section will define the concepts involved in using generic, corporate, and international strategies. These basic concepts defined will …show more content…

In this section I will define the following corporate strategies. Horizontal integration occurs when a business expands its control over other similar or closely related businesses. Vertical integration occurs when a business expands its control over other business that are part of its overall manufacturing process. Related diversification is a process that takes place when a business expands its activities into product lines that are similar to those it currently offers. Unrelated diversification is a process that takes place when a business expands its activities into product lines that are not similar to those it currently …show more content…

Pfizer has little pressure to respond to local wishes. This is also due to the fact that Pfizer cannot apply adaptations to a product which has costs years to develop and has costs millions to market. This is also supported by the fact that Pfizer licenses their products on very strict terms which do not allow any changes to the drugs. Since Pfizer needs to maximize returns during the patent protected time of its products it should use an International strategy.

4. EVALUATION
4.1. Problem:
The problem Pfizer is some unsuccessful partnership experience with companies in foreign markets. One factor that resulted in unsuccessful partnership experience were internal high pressure to achieve a foot hold in the market place by using joint ventures.
4.2. Solution:
One solution to lowering unsuccessful partnership is for Pfizer to adapt to the changing environment by morphing into a dynamic company that is well-positioned for the future of pharmaceuticals industry. That uses a hybrid approach to conquering foreign markets utilizing a multitude of strategies. Pfizer should continue to expand overseas to take advantage of changes in the global economy. Further, expansion overseas will lessen the Company’s reliance on the U.S. economy which is becoming less of a profitable environment due to the entrance of the government via Medicare Part D and through our national health

Show More
Related

  • Medtronic Case Analysis

    2105 Words  | 5 Pages

    The current health care landscape has been characterized by large scale consolidation and vertical integration of payers and providers. This has led to a handful of dominate players with substantial influence, and an increasing overlap in responsibilities between payers and providers. Although payers and providers have traditionally been on opposing sides, battling each other about quality of care versus cost-effective care, they are shifting to working together to achieve better value.

    Read More

  • Megadeal Unites Drug Rivals

    959 Words  | 2 Pages

    This consolidation, along with others in the health services industry, factors a drive to cut costs and thus, increase revenues. By combining purchasing power and control over a large percentage of the drug industry, PBM’s can negotiate reductions in drug costs for themselves and their consumers. They can procure less expensive generic drugs from generic manufacturers, negotiate rebates and disc...

    Read More

  • Case Study: Merck & Co.

    1303 Words  | 3 Pages

    Background: Merck & Co. is an American pharmaceutical company and one of the largest pharmaceutical companies in the world. In 1971 the United States approved the use of an MMR vaccine made by Merck, containing the Jeryl Lynn strain of mumps vaccine. In 1978 Merck introduced the MMR II, using a different strain of the rubella vaccine. In 1997 the FDA required Merck to conduct effectiveness testing of MMRII. Initially it was over 95%; to continue the license; Merck had to convince the FDA that the effectiveness stayed at a similar rate over the years.

    Read More

  • The Meaning of Vertical and Horizontal Integration

    752 Words  | 2 Pages

    The Meaning of Vertical and Horizontal Integration Horizontal integration is where an organisation owns two or more companies, on the same level of the buying chain. An example of this is the First Choice Group; they own First Choice Travel Agency and First Choice Hypermarket, both of which are on the same level of the buying chain. The advantage of horizontal integration is that it can increase the company’s market share. Another good example of this type of integration is when EasyJet purchased the airline Go from British Airways. Now EasyJet and Go both operate under the company name of EasyJet.

    Read More

  • Examples Of Porter's Generic Strategy Typology And The Miles And Snow Strategy

    965 Words  | 2 Pages

    Porter’s generic strategy typology and the Miles and Snow strategy typology are both examples of generic strategic models that a decision maker may find useful (Parnell, 2014). Both generic strategy frameworks explain generic business strategies by utilizing four different strategy types. A few of the strategies may share some common traits, however the frameworks are different in the approach they take to view and describe strategies (Parnell, 2014).

    Read More

  • Eli Lilly And Company: The Global Pharmaceutical Company

    1326 Words  | 3 Pages

    Threat of new entrants is relatively high. Companies forming alliances are potential rivals. Even if earlier such company was not considered to be a threat, after merging with some research and development company or forming alliance with another pharmaceutical company it would become a rival to Eli Lilly. The threat is however weakened by significant research and development costs necessary to successfully enter the business. Eli Lilly’s focus on a relatively narrow market of sedatives and antidepressants weakens the threat of new entrants, but other products that form lesser part of company’s sales such as insulin and others are exposed to high threat of new entrants. The need of obtaining certificates and licenses also weakens the threat of new entrants. Discussed above leads to the conclusion that threat of new entrants is medium.

    Read More

  • The Power and Benefits of Monopolies in the Pharmaceutical Industry

    1993 Words  | 4 Pages

    This fact validates the incentive pharmaceutical companies have to get a patent and acquire more power. Pfizer encourages R&D because of the incentives and a desire to obtain patents to receive more profit. Pfizer has to promote itself to be successful, creating a brand image that consumers will trust. If the company can advertise successfully, more consumers will purchase their products. Pfizer must also be generating products efficiently in order to save and use existing resources, while manufacturing their products at low costs to stay competitive....

    Read More

  • Exploring Walt Disney Company: The Entertainment King

    1511 Words  | 4 Pages

    ...ative aspects of diversification, for example through better corporate planning, human recourse management and reaching further synergies between its various business lines.

    Read More

  • Business Analysis: Merck & Co.

    1393 Words  | 3 Pages

    10. Collis, David, and Troy Smith. "Strategy in the Twenty-First Century Pharmaceutical Industry:Merck&Co. and Pfizer Inc." Harvard Business School, 2007: 8-12.

    Read More

  • A Business Model Analysis of Eli Lilly and Company

    2081 Words  | 5 Pages

    Zott, C., Amit, R. And Massa, L. (2011) ‘The Business Model: Recent Developments and Future Research’, Journal of Management, vol.37, no.4 pp.1019-42 [Online]. Available at http://jom.sagepub.com/content/37/4/1019 [Accessed 24th November 2013]

    Read More

  • Eli Lilly and Company Case Analysis

    1605 Words  | 4 Pages

    The case under analysis, Eli Lilly & Company, will be covering the positives and negatives with regards to the business situation and strategy of Eli Lilly. One of the major pharmaceutical and health care companies in its industry, Lilly focused its efforts on the areas of "drug research, development, and marketed to the following areas: neuroscience, endocrinology, oncology, cardiovascular disease, and women's health." Having made a strong comeback in the 1990's due to its remarkably successful antidepressant Prozac, was now facing a potential loss in profits with its patent soon to expire. The problem was not only the soon to expire patent on Prozac, but the fact that Prozac accounted for as much as 30% of total revenue was the reality Eli Lilly now faced. (Pearce & Robinson, 34-1)

    Read More

  • Business Analysis of Teva Pharmaceuticals

    2720 Words  | 6 Pages

    For commodity generic drugs, Teva has an opportunity to expand its core business into emerging markets, but there it will have to face institutional voids because such markets are driven by physicians and both physician and other people are not aware about the effectiveness of generic drugs. To cope with the challenge of institutional voids Teva have to look for some competent small pharmaceutical firms for acquisition and some big firms for the joint venture. For changing the perceptions of people and physicians, Teva will require to run marketing campaigns and direct approaches to physicians to develop a market for their products.

    Read More

  • Difference Between Porter And Miles And Snow's Strategy Typology

    736 Words  | 2 Pages

    Both Porter and Miles and Snow’s strategy typologies are based on the concept of strategic equifinality, or the ability for firms to be successful via differing managerial strategies (Hambrick, 2003, p. 116). Porter 's strategy is more generic while Miles and Snow’s is more specific in nature. Porter’s generic strategy typology is based on economic factors centering on the source of a firm’s competitive advantage and the scope of a firm’s target market (González-Benito & Suárez-González, 2010). Porter’s typology emphasizes a firm’s cost, product differentiation or non-differentiation and market focus. When utilizing Porter’s strategy typology, a firm must first decide to target its products toward the mass market versus a market niche or focus. Secondly, a firm will determine if it wishes to minimize costs or differentiate its products with differentiation meaning that firms will most likely forego lower costs (Parnell, 2014, p. 184). This can lead a firm to develop a myriad of strategies between these options. Strategies which may have or not have focus, may or not be differentiated, may or not be low cost or any combination of strategies. In contrast to Porter, Miles and Snow’s typology is more specific in nature.

    Read More

  • An Analysis of Johnson & Johnson

    2815 Words  | 6 Pages

    ... global marketplace, it is also essential that Johnson & Johnson focuses on the critical drivers of their future growth: to create value through innovation, to extend their global reach, with local focus, to execute with excellence in everything it does and to inspire leadership with purpose among the people who carry on the Johnson & Johnson legacy.

    Read More

  • An Overview of Business Strategies

    2251 Words  | 5 Pages

    There are four main business strategies that can be used they are Cost leadership strategy, Differentiation strategy, Focus strategy (low cost) and Focus strategy (differentiation). We can use Porter’s generic business strategies to understand the difference in these strategies.

    Read More

More about Strategic Analysis Of Pfizer

Open Document